OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria. CEO is Elisabeth Lindner.
- Funding €6M (November)
- Funding €32M (November)
ExitNo exit added
The content of this page is partly user generated and not controlled by the Nordic Tech List editorial team, nor is it part of the Nordic Tech List editorial database: Nordictechlist.com. For more info see FAQ.